Carlos V. Paya, Russell H. Wiesner, Paul E. Hermans, Jeffrey J. Larson‐Keller, Duane M. Ilstrup, Ruud A. F. Krom, S. Breanndon Moore, Jurgen Ludwig, Thomas F. Smith – 1 July 1992 – In this study we evaluated the association between cytomegalovirus infection alone or in relation to human leukocyte antigen matching and the development of vanishing bile duct syndrome, a form of chronic hepatic allograft rejection.

1 July 1992

Jeremiah P. Donovan, Byers W. Shaw, Alan N. Langnas, Michael F. Sorrell – 1 July 1992

Norman L. Sussman, Maria G. Chong, Tarek Koussayer, Da‐Er He, Thomas A. Shang, Hartwell H. Whisennand, James H. Kelly – 1 July 1992 – Liver transplantation is currently the only effective therapy for patients with fulminant hepatic failure. The availability of an artificial liver could bridge these patients through the relatively brief crisis period and allow their own livers to regenerate, providing a more favorable outcome and sparing the trauma and expense of transplant.

Shuichi Okada, Nobuo Okazaki, Haruhiko Nose, Masayoshi Yoshimori, Kazunori Aoki – 1 July 1992 – A total of 71 consecutive patients with unresectable hepatocellular carcinoma were analyzed retrospectively to determine the significant prognostic factors. All the patients received systemic chemotherapy in a phase 2 study from 1980 to 1990, with no other anticancer treatment. Median survival time and 1‐yr and 2‐yr survival rates were 5.6 mo, 23% and 5%, respectively.

Luis Sanchez‐Urdazpal, Gregory J. Gores, Ellen M. Ward, Timothy P. Maus, H. Erik Wahlstrom, S. Breanndan Moore, Russell H. Wiesner, Ruud A. F. Krom – 1 July 1992 – Nonanastomotic biliary strictures that involve only the biliary tree of the graft occur after orthotopic liver transplantation in patients with hepatic artery thrombosis, chronic ductopenic rejection and ABO blood group incompatibility. This complication may also occur in the absence of these known risk factors.

Chen‐Kung Chou, Li‐Hsien Wang, Hsing‐Mei Lin, Chin‐Wen Chi – 1 July 1992 – Glucocorticoids have been shown to influence the severity of hepatitis B virus–related chronic hepatitis in human. However, very little is known about the effects of glucocorticoids on hepatitis B virus replication in vitro. In this report, we used a welldifferentiated human hepatoma cell line, Hep3B, transfected with hepatitis B virus complementary DNA as a model to show that a glucocorticoid analog, dexamethasone, can directly stimulate the production of HBsAg and HBeAg.

Shigetoshi Fujiyama, Shiro Iino, Koichi Odoh, Shoji Kuzuhara, Hiroaki Watanabe, Masahiko Tanaka, Kyosuke Mizuno, Tatsuo Sato – 1 June 1992 – To investigate the antibody titer necessary to prevent hepatitis A virus infection, either 15 or 7.5 mg/kg of immune serum globulin was injected into 10 antihepatitis A virus negative volunteers and their serum antihepatitis A virus titers were observed for 28 wk. In addition, antibody titers were observed for 96 wk in a phase 1 clinical trial of a hepatitis A vaccine.

Lola M. Reid, Anthony S. Fiorino, Samuel H. Sigal, Shlomo Brill, Patricia A. Holst – 1 June 1992

Jarbas R. de Oliveira, Jose Luis Rosa, Santiago Ambrosio, Ramon Bartrons – 1 June 1992 – Intraperitoneal administration of galactosamine (400 mg/kg body wt) to rats results in reversible liver cell injury that is related to a dose‐dependent depletion of uridine phosphates by formation of UDP‐sugar derivatives. This damage was monitored through changes in serum enzymatic activities that increased after the first 6 hr of drug administration. Glycemia and serum albumin remained stable during liver injury, whereas cholesterol and triglycerides decreased.